April 18th 2025
The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Improving Aggregate Removal to Enhance Clinical Manufacturing of MAbs
September 28th 2018Hydrophobic interaction chromatography (HIC) in flow-through mode offers a more efficient and cost-effective polishing/purification process to remove monoclonal antibody aggregates while maintaining purity at ≥99% than a mixed-mode bind/elute procedure.
BeiGene Selects GE Healthcare’s Biologics Factory to Boost its Manufacturing Capacity
September 20th 2018BeiGene is set to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies.
Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Perfusion-Enabled Bioreactors
September 4th 2018A collaboration integrates Sartorius Stedim Biotech’s BIOSTAT STR bioreactors and Repligen’s XCell ATF cell-retention control technology to create simplified, scalable equipment for intensified cell culture.